Table 4.
Pilot study – outcomes of medicines review
| Patient | PIP | Outcome of review |
|---|---|---|
| 1 |
PPI |
Dose reduction |
| TCA and CCB |
TCA discontinued |
|
| 2 |
PPI |
Dose reduction |
| Therapeutic duplication - ACE and ARB |
ARB discontinued |
|
| 3 |
Long term long acting benzodiazepine |
Dose reduction |
| 4 |
PPI |
Dose reduction |
| 5 |
Bladder antimuscarinics and constipation |
Left unaltered |
| 6 |
NSAID and diuretic |
NSAID discontinued |
| 7 |
NSAID and ACE |
NSAID discontinued |
| 8 | Long term steroid for maintenance therapy in COPD/Asthma | Switched from steroid to other treatment |
Abbreviations: ACEI Angiotensin-converting-enzyme inhibitor, ARB Angiotensin II receptor blockers, CCB Calcium channel blocker, COPD Chronic obstructive pulmonary disease, NSAID Nonsteroidal anti-inflammatory drugs, PPI Proton pump inhibitor, TCA Tricyclic anti-depressant.
Note: The decision on whether to follow the recommended treatment alternatives will be at the discretion of the GP, weighing up the risks and benefits and patient preference.